COVID-19 and Pasteurella multocida Pulmonary Coinfection : A Case Series
OBJECTIVES: In COVID-19 patients, bacterial and fungal pulmonary coinfections, such as Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, or Aspergillus, have been reported, but to our knowledge, no case has been reported due to Pasteurella multocida.
PATIENTS AND METHODS: We describe three cases of Pasteurella multocida coinfections occurring during the 4th wave of COVID-19 in Martinique (French West Indies).
RESULTS: All three cases were fatal; thus, Pasteurella multocida has to be considered as a potentially severe coinfection agent.
CONCLUSIONS: Alteration of the epithelial-endothelial barrier due to a SARS-CoV-2 infection probably promotes the expression of a Pasteurella infection. In addition, the SARS-CoV-2 infection induced immunosuppression, and an inflammatory cascade could explain the infection's severity. The use of corticosteroids, which are part of the first-line therapeutic arsenal against COVID-19, may also promote the pathogenicity of this agent.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Tropical medicine and infectious disease - 7(2022), 12 vom: 11. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cabras, Ornella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 coinfection |
|---|
| Anmerkungen: |
Date Revised 25.12.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/tropicalmed7120429 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350602123 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350602123 | ||
| 003 | DE-627 | ||
| 005 | 20231226045352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/tropicalmed7120429 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350602123 | ||
| 035 | |a (NLM)36548684 | ||
| 035 | |a (PII)429 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cabras, Ornella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and Pasteurella multocida Pulmonary Coinfection |b A Case Series |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a OBJECTIVES: In COVID-19 patients, bacterial and fungal pulmonary coinfections, such as Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, or Aspergillus, have been reported, but to our knowledge, no case has been reported due to Pasteurella multocida | ||
| 520 | |a PATIENTS AND METHODS: We describe three cases of Pasteurella multocida coinfections occurring during the 4th wave of COVID-19 in Martinique (French West Indies) | ||
| 520 | |a RESULTS: All three cases were fatal; thus, Pasteurella multocida has to be considered as a potentially severe coinfection agent | ||
| 520 | |a CONCLUSIONS: Alteration of the epithelial-endothelial barrier due to a SARS-CoV-2 infection probably promotes the expression of a Pasteurella infection. In addition, the SARS-CoV-2 infection induced immunosuppression, and an inflammatory cascade could explain the infection's severity. The use of corticosteroids, which are part of the first-line therapeutic arsenal against COVID-19, may also promote the pathogenicity of this agent | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 coinfection | |
| 650 | 4 | |a Pasteurella multocida pulmonary infection | |
| 650 | 4 | |a ventilator-acquired pneumonia | |
| 700 | 1 | |a Turmel, Jean-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Olive, Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Bigeard, Bastien |e verfasserin |4 aut | |
| 700 | 1 | |a Lehoux, Mélanie |e verfasserin |4 aut | |
| 700 | 1 | |a Pierre-Francois, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Guitteaud, Karine |e verfasserin |4 aut | |
| 700 | 1 | |a Abel, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Cuzin, Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Cabié, André |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tropical medicine and infectious disease |d 2016 |g 7(2022), 12 vom: 11. Dez. |w (DE-627)NLM275181960 |x 2414-6366 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:12 |g day:11 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/tropicalmed7120429 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 12 |b 11 |c 12 | ||